Prescribed PT-141
Between 1267 women and a PT-141 prescription
A prescription concerns a particular person. Bremelanotide’s strongest evidence concerns group averages. Those averages leave me curious about the person whose decision still lies ahead.
Trial averages. Individual decisions.

1267 women in RECONNECT
The two RECONNECT trials enrolled 1267 premenopausal women with hypoactive sexual desire disorder, or HSDD: persistently low desire that causes distress. Over 24 weeks, bremelanotide improved desire scores and reduced distress compared with placebo. Both trials met their main endpoints. The repeated result persuaded me to give the finding weight.
Then comes the harder step. A prescription is written for someone whose response has yet to happen. The average improvement leaves room for benefit that feels worthwhile, benefit that feels slight, and disappointment. I consider the gap between a result in a group and a decision for a person more consequential than the phrase “desire drug” suggests.
What is PT-141?
PT-141 is the development name for bremelanotide, a synthetic ring of seven amino acids that activates melanocortin receptors in the brain. Its principal target, MC4R, participates in sexual motivation; the same receptor also has a role in appetite. The name sounds like a laboratory code because that is where the story began.
The U.S. FDA approved bremelanotide injection on June 21, 2019, under NDA 210557, for acquired, generalized HSDD in premenopausal women. That describes a specific diagnosis and population. The approved use excludes men, postmenopausal women and sexual-performance enhancement. Material described as a research chemical sits outside this approval.
The individual response
The integrated trial differences were FSFI-desire +0.35 and FSDS-DAO item 13 −0.33 versus placebo, both P<.001. These desire and distress scores describe different aspects of the experience; the numbers need their respective scales. The temptation to compress them into a prediction of how somebody will feel strikes me as a mistake.
A modest average can be useful evidence without answering that personal question. The benefits page looks closely at the measurements. The study register separates the controlled trials from the extension and the smaller brain-imaging experiment.
Tolerability
In the 52-week open-label extension, 684 women enrolled, desire improvements were sustained and no new safety signals emerged. Nausea occurred in 40.4%, flushing in 20.6% and headache in 12.0% as drug-related treatment-emergent events. Those figures make the personal calculation more complicated.
The prescribing information also warns about transient blood-pressure increases and contraindicates the medicine in uncontrolled hypertension or known cardiovascular disease. A group result about benefit cannot cancel a person’s clinical exclusion. The effects and safety account brings those cautions together.
Prescribing decisions
For me, “prescribed” points to the work still required after a trial reports success: a licensed clinician assessing a particular person’s health, the approved indication and the balance of possible benefit and harm. Approval supplies a defined use; it leaves that individual judgement to clinical care.
The dose record covers the label and research history. For the biology behind the scores, start with how PT-141 works.